Needham & Company Downgrades Seattle Genetics (SGEN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Seattle Genetics (SGEN) in Focus After Tops Q4 EPS by 2c, Provides Outlook
February 13, 2013 7:52 AM ESTSeattle Genetics Inc. (NASDAQ: SGEN) reported Q4 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $35.35 million versus the consensus estimate of $57.21 million.
2013 Financial Outlook
Seattle Genetics anticipates that revenues from ADCETRIS net product... More
